KORIAN (KORI.PA)       20.52  -0.18 (-0.87%)

20.52  -0.18 (-0.87%)

FR0010386334 - Common Stock


Fundamental Rating

Taking everything into account, KORI scores 3 out of 10 in our fundamental rating. KORI was compared to 9 industry peers in the Health Care Providers & Services industry. KORI has a bad profitability rating. Also its financial health evaluation is rather negative. KORI has a correct valuation and a medium growth rate.




Profitability

Profitability Rating


The Piotroski-F score of KORI is 7.00. This is a strong score and indicates good health and profitability for KORI.
KORI's Return On Assets of 0.66% is worse than the rest of the industry. The industry average Return On Assets is 2.53%. 100% of the industry peers have a better Return On Assets.

KORI's Return On Equity of 2.70% is worse than the rest of the industry. The industry average Return On Equity is 9.57%. 88% of the industry peers have a better Return On Equity.
KORI has a Profit Margin of 2.28%. This is below the industry average of 4.63%. 88% of the industry peers outperform KORI.
VS Industry

ROA (0.66%) VS Industry: 0% outperformed.

0.66
11.51

ROE (2.7%) VS Industry: 12% outperformed.

1.88
27.68

Profit Margin (2.28%) VS Industry: 12% outperformed.

0.55
16.59

Valuation

Valuation Rating


When comparing the current price to the book value of KORI, it is valued rather cheaply. It is trading at 0.62 times its book value.
When comparing the price book ratio of KORI to the average industry price book ratio of 1.67, KORI is valued rather cheaply. KORI is also cheaper than 87% of the companies listed in the same industry.
When comparing the Enterprise Value to EBITDA ratio of KORI to the average industry ratio of 9.10, KORI is valued rather cheaply.
With a Price/Earnings Ratio of 20.32, KORI is valued on the expensive side.

The Forward Price/Earnings Ratio of 16.12 indicates a correct valuation of KORI.
The PEG Ratio, which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
With a Price/Earning Ratio of 20.32, KORI is valued a higher than the industry average, which is at 16.50. 88% of the companies listed in the same industry are cheaper than KORI!
VS Industry

Price/Earnings (20.32) VS Industry: 12% outperformed.

69.72
5.81

Price/Book (0.62) VS Industry: 87% outperformed.

3.82
0.58

Enterprise Value/ EBITDA (9.06) VS Industry: 66% outperformed.

14.51
4.48

Growth

Growth Rating


KORI shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 138.23%, which is quite impressive.
KORI is expected to show quite a strong growth in Earnings Per Share. In the coming 5 years, the EPS will grow by 18.39% yearly.
When comparing the EPS growth rate of the last 5 years to the growth rate of the upcoming 5 years, we see that the growth is accelerating.
The Revenue has grown by 10.08% in the past year. This is quite good.

Measured over the past 5 years, KORI shows a decrease in Earnings Per Share. The EPS has been decreasing by -8.00% on average per year.
Measured over the past 5 years, KORI shows a small growth in Revenue. The Revenue has been growing by 6.86% on average per year.
The Revenue is expected to grow by 6.38% on average over the next 5 years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming 5 years, we see that the growth is stable.

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPS-8% -8.21% 138.23% 17.52% 19.87% 18.62% 18.39%
Revenue6.86% 7.6% 10.08% 7.89% 7.27% 6.98% 6.38%

Health

Health Rating


The Piotroski-F score of KORI is 7.00. This is a strong score and indicates good health and profitability for KORI.
KORI has a Quick Ratio comparable to the industry average, which is at 0.87.
A Current Ratio of 0.88 indicates that KORI may have some problems paying its short term obligations.
Compared to an average industry Current Ratio of 1.10, KORI is worse placed to pay its short term obligations than its industry peers.

KORI has a Quick Ratio of 0.88. This is a bad value and indicates that KORI is not financially healthy enough and could expect problems in meeting its short term obligations.
When comparing the Debt to Equity Ratio of KORI to the average industry Debt to Equity Ratio of 1.00, KORI required more debt to finance its operations than its industry peers.
Based on the Altman-Z score of 0.64, we must say that KORI is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of KORI to the average industry Altman-Z score of 1.54, KORI is less financially healthy than its industry peers. 88% of its industry peers have a better Altman-Z score.
VS Industry

Debt/Equity (2.04) VS Industry: 25% outperformed.

3.06
0.04

Quick Ratio (0.87) VS Industry: 50% outperformed.

0.49
2.82

Current Ratio (0.88) VS Industry: 25% outperformed.

0.65
3.21

Altman-Z (0.64) VS Industry: 12% outperformed.

0.53
7.02

Dividend

Dividend Rating


KORI pays out 38.51% of its income as dividend. This is a sustainable payout ratio.
KORI has a Yearly Dividend Yield of 1.78%. Purely for dividend investing, there may be better candidates out there.
Compared to an average industry Dividend Yield of 2.24, KORI has a dividend in line with its industry peers.

KORI's Dividend Yield is comparable with the S&P500 average which is at 2.14.
The dividend of KORI decreases each year by -14.20%.
VS Industry

Dividend Yield (1.78%) VS Industry: 42% outperformed.

0.40
2.75
KORI Daily chart

KORIAN20.52

EPA:KORI (5/16/2022, 5:29:41 PM)-0.18 (-0.87%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Providers & Services
Earnings (Last) N/A N/A Earnings (Next) N/A N/A
Ins Owners N/A Inst Owners N/A
Market Cap 2.17B Analysts 83.33
Valuation
PE 20.32 Fwd PE 16.12
PEG (NY) 1.16 PEG (5Y) N/A
P/S 0.52 P/B 0.62
EV/EBITDA 9.06
Profitability
ROA 0.66% ROE 2.7%
PM 2.28 Asset Turnover 0.29
Growth
EPS 1Y 138.23% EPS 3Y -8.21%
EPS 5Y -8% EPS growth Q2Q 142.08%
EPS Next Y 17.52% EPS Next 2Y 19.87%
EPS Next 3Y 18.62% EPS Next 5Y 18.39%
Revenue growth 1Y 10.08% Revenue growth 3Y 7.6%
Revenue growth 5Y 6.86% Revenue growth Q2Q 10.97%
Revenue Next Year 7.89% Revenue Next 2Y 7.27%
Revenue Next 3Y 6.98% Revenue Next 5Y 6.38%
Health
Current Ratio 0.88 Quick Ratio 0.87
Altman-Z 0.64 F-Score 7
Debt/Equity 2.04
Dividend
Dividend Yield 1.78% Dividend Growth -14.2%
DP 38.51% Ex-Date N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the EuroNext

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the EuroNext

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the EuroNext

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the EuroNext